文献速递治疗药物监测与药物基因组学肝肾功能剂量调整

CYP3A5*3/*3与CYP3A4*22/*22基因型组合对四例肾移植患者他克莫司消除的影响

Tacrolimus Elimination in Four Patients With a CYP3A5*3/*3 CYP3A4*22/*22 Genotype Combination.
PubMed 文献 · Pharmacotherapy · 2018-06-27

该研究从1366例白人肾移植受者中识别出4例携带CYP3A5*3/*3和CYP3A4*22/*22罕见基因型组合的患者,比较其与他克莫司谷浓度及剂量的关系。结果显示,与CYP3A5*1/*1和CYP3A4*1/*1组合相比,该组合中位剂量归一化谷浓度增加342%;与CYP3A5*3/*3和CYP3A4*1/*1组合相比增加90.6%。这4例患者平均仅需他克莫司2.5 mg/天,提示认识该基因型有助于选择合适剂量以避免过度暴露。

要点

  • CYP3A5*3/*3和CYP3A4*22/*22组合罕见但显著降低他克莫司代谢。
  • 该组合患者他克莫司剂量归一化谷浓度较野生型组合增加342%。
  • 该组合患者平均他克莫司需求量仅2.5 mg/天,需警惕过度暴露。

核心结论

  • 同时携带CYP3A5*3/*3和CYP3A4*22/*22基因型的肾移植患者他克莫司代谢显著降低,需减少剂量以避免过度暴露。

研究设计与样本

  • 研究描述4例携带CYP3A5*3/*3和CYP3A4*22/*22基因型组合的白人肾移植受者,来自1366例白人肾移植受者队列,并与无该组合的受者进行比较。

主要发现

  • 与CYP3A5*1/*1和CYP3A4*1/*1组合相比,CYP3A5*3/*3和CYP3A4*22/*22组合的中位剂量归一化谷浓度增加342%。
  • 与CYP3A5*3/*3和CYP3A4*1/*1组合相比,CYP3A5*3/*3和CYP3A4*22/*22组合的中位剂量归一化谷浓度增加90.6%。
  • 这4例患者平均他克莫司需求量为2.5 mg/天。

临床怎么用

  • 对肾移植受者进行CYP3A5和CYP3A4基因分型有助于识别他克莫司代谢显著降低的高风险患者。
  • 对携带CYP3A5*3/*3和CYP3A4*22/*22基因型组合的患者,应选择较低的他克莫司剂量并密切监测谷浓度以避免过度暴露。

局限性

  • 研究仅描述4例患者,样本量小,结论需更大规模研究验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Cytochrome P450 3A5 (CYP3A5) and cytochrome P450 3A4 (CYP3A4) are the predominate enzymes responsible for tacrolimus metabolism. The presence of CYP3A4 and CYP3A5 genetic variants significantly affects tacrolimus clearance and dose requirements. CYP3A5*3 is a loss-of-function variant resulting in no CYP3A5 enzyme production. CYP3A4*22 is a variant that reduces production of functional CYP3A4 protein. Caucasians commonly carry these variant alleles but are very rarely homozygous for both CYP3A5*3 and CYP3A4*22. This report describes four kidney transplant recipients who carry a rare genotype combination (CYP3A5*3/*3 and CYP3A4*22/*22). These patients were identified from a larger cohort of Caucasian kidney transplant recipients (n=1366). To understand the significance of this genotype combination on tacrolimus troughs and doses, we compared these patients to recipients without this combination. Patients homozygous for both variants are at risk for profound reductions in metabolism of CYP3A substrates. A 342% and a 90.6% increase in the median dose-normalized trough was observed, when the CYP3A5*3/*3 and CYP3A4*22/*22 genotype combination was compared to the CYP3A5*1/*1 and CYP3A4*1/*1 genotype combination and the CYP3A5*3/*3 and CYP3A4*1/*1 genotype combination, respectively. These four individuals only required on average 2.5 mg/day of tacrolimus. Knowledge of these genotypes would be useful in selecting appropriate tacrolimus doses to avoid overexposure.

来源:Pharmacotherapy,查看原文。版权归原作者所有。

引用

  1. Scheibner A, Remmel R, Schladt D, et al. Tacrolimus Elimination in Four Patients With a CYP3A5*3/*3 CYP3A4*22/*22 Genotype Combination. Pharmacotherapy. 2018. PMID: 29804290. doi:10.1002/phar.2131

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。